Development PipelineSGN-CD228A

an investigational antibody–drug conjugate directed to CD228

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGN228A-001: Advanced solid tumors

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SGN-CD228A and ongoing clinical trials

Detailed information about SGN–CD228A clinical trials